December 4, 2025Expert Review of Cardiovascular Therapy

Use of sodium–glucose cotransporter 2 inhibitor in heart failure: a real-world study

View Full Paper

Ask AI

Bookmark

Authors

MLMaría Fernanda Lerma-BarcoFundación Universitaria Autónoma De Las Américas AFAna Sofia Franco-CarvajalFundación Universitaria Autónoma De Las Américas JMJorge Enrique Machado‐AlbaTechnological University of Pereira

Discussion

Member takes

Implication

Real-world evidence shows similar adherence to SGLT2 inhibitors in heart failure patients, suggesting possible benefits for those with high comorbidities.

Key Points

Adherence to SGLT2 inhibitors remains high in heart failure patients, indicating treatment stability.
Patients with heart failure often present a high comorbidity burden and require effective management strategies.
Real-world evidence studies support the effectiveness of SGLT2 inhibitors in heart failure treatment.
These findings may highlight the role of comprehensive care in improving medication persistence among patients.

Cite This Study

Lerma-Barco et al. (2025) studied this question.

synapsesocial.com/papers/6930dc6bea1aef094cca1f5d https://doi.org/10.1080/14779072.2025.2598405

View Full Paper

Ask AI

Bookmark

Implication

Real-world evidence shows similar adherence to SGLT2 inhibitors in heart failure patients, suggesting possible benefits for those with high comorbidities.

Use of sodium–glucose cotransporter 2 inhibitor in heart failure: a real-world study

Discussion

Member takes

Implication

Key Points

Cite This Study

Use of sodium–glucose cotransporter 2 inhibitor in heart failure: a real-world study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider